FDA Approval of Tisagenlecleucel Promise and Complexities of a $475 000 Cancer Drug

被引：132

作者：

Bach, Peter B. ^{[1
]}

Giralt, Sergio A. ^{[1
]}

Saltz, Leonard B. ^{[1
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, 485 Lexington Ave,Second Floor, New York, NY 10017 USA

来源：

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2017年 / 318卷 / 19期

基金：

美国国家卫生研究院;

关键词：

D O I：

10.1001/jama.2017.15218

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1861 / 1862

页数：2

共 9 条

[1] Payer and Policy Maker Steps to Support Value-Based Pricing for Drugs [J].

Bach, Peter B. ;

Pearson, Steven D. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 314 (23) :2503-2504

[2] New Math on Drug Cost-Effectiveness [J].

Bach, Peter B. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (19) :1797-1799

[3] Indication-Specific Pricing for Cancer Drugs [J].

Bach, Peter B. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2014, 312 (16) :1629-1630

[4]

Drug Pricing Lab Report, 2017, IND SPEC PRIC PATHW

[5] Pricing in the Market for Anticancer Drugs [J].

Howard, David H. ;

Bach, Peter B. ;

Berndt, Ernst R. ;

Conti, Rena M. .

JOURNAL OF ECONOMIC PERSPECTIVES, 2015, 29 (01) :139-162

[6]

KALTENBOECK A., 2017, Outcomes-Based Drug Contracts Do Not Move Us Closer to Value

[7]

[Novartis FDA], 2017, ONC DRUGS ADV COMM B

[8]

Price & Value of Cancer Drug, PRIC VAL CANC DRUG

[9] ANTI-LEUKEMIC EFFECT OF GRAFT VERSUS HOST DISEASE IN HUMAN RECIPIENTS OF ALLOGENEIC MARROW GRAFTS [J].

WEIDEN, PL ;

FLOURNOY, N ;

THOMAS, ED ;

PRENTICE, R ;

FEFER, A ;

BUCKNER, CD ;

STORB, R .

NEW ENGLAND JOURNAL OF MEDICINE, 1979, 300 (19) :1068-1073

← 1 →